Science at the service of the community. In the city of Guadalajara, Mexico, a group of scientists works to help in a clinical trial. The idea, the most importantly, is to develop effective treatments against COVID-19, and maybe, a vaccine. They have already obtained the difficult Mexican certification to carry out the study. This is the first protocol against the coronavirus made by the private initiative in Mexico, like CidVID explains the press release.
The scientists are part of the biometric research company CidVID. Based in Mexico but with a global presence. Starting June this year, a team of scientists, doctors, and patient volunteers will make Silver Bullet a reality, as they named their study, a title with several readings, all positive.
Against covid-19: science for the common health
The first phase consists of communicating to patients diagnosed with COVID-19. With mild or moderate symptoms, the possibility of participating in this study, its characteristics, and the value of contributing to solutions aimed at a common benefit. Also, the company opened a fund to support this initiative on the Fondify website.
In technical terms, Silver Bullet, in other words, it is a “Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of a drug in Mild Virus-positive Subjects (SARS-COV-2 ) with or without symptoms”. The name was taken from some capital letters of the study. Also, referring to a commitment to the common good to combat the COVID-19 pandemic, which already has millions of victims worldwide.
CidVID is a Mexican company dedicated to the development and conduct of clinical studies in its different phases. For example, pharmaceuticals, nutraceuticals, medical devices, and any product that seeks to demonstrate efficacy and safety. The company works with the most important laboratories in the world. Conducting clinical research with the highest quality and under international standards and legislation.
For more information and ways to support this initiative and Latin American science against COVID-19, click here.